Cannabinoid receptor agonist 13, a novel cannabinoid agonist: first in human pharmacokinetics and safety.
Cannabinoid receptor agonist 13 (CRA13) is a novel cannabinoid (CB) receptor agonist with high affinity and functional activity toward both CB(1) and CB(2) receptors. This phase I study aimed to evaluate the pharmacokinetics, safety, and tolerability of single oral doses of CRA13. Sixty-three of 69 healthy adult males were randomized in seven cohorts (n = 9) to receive 1 to 80 mg of CRA13 or placebo orally in fasted condition. To investigate the diet effect, an independent group (n = 6) was randomized to receive 40 mg of CRA13 after high-fat and high-calorie breakfast in crossover design with a 2-week washout period. Peak plasma concentration (C(max)) ranged from 7.8 to 467.6 ng/ml (1-80 mg). CRA13 was rapidly absorbed and demonstrated linear pharmacokinetics (1-80 mg). Time to reach C(max) (t(max)) was 1.5 to 2 h for all doses in both fasted and fed groups. Administration of 40 mg of CRA13 with food induced approximately 2-fold increase in the C(max) and the area under the concentration-time curve, AUC(0 - tz). The apparent elimination half-life (t(1/2)) was 21 to 36 h and 30 to 41 h for fasted and fed groups, respectively. Dizziness, headache, and nausea were the most frequently reported adverse events (AEs), predominantly at the 40- and 80-mg doses. The incidence of AEs was dose-dependent and mild to moderate. No deaths and serious adverse events were reported. In conclusion, CRA13 was reasonably well tolerated and demonstrated a linear pharmacokinetics over the studied dose range (1-80 mg). Food intake increased CRA13 C(max) and AUC(0 - tz) by approximately 2-fold, whereas t(max) was unaffected.
Gardin
Anne
A
Novartis Institutes for BioMedical Research, Basel, CH-4002, Switzerland. anne.gardin@novartis.com
Kucher
Klaus
K
Kiese
Beate
B
Appel-Dingemanse
Silke
S
D019540:Area Under Curve; D063386:Cannabinoid Receptor Agonists; D015331:Cohort Studies; D004311:Double-Blind Method; D006207:Half-Life; D006801:Humans; D008297:Male; D009281:Naphthalenes / Q000009:adverse effects* / Q000493:pharmacokinetics* / Q000494:pharmacology; D010919:Placebos
D063386:Cannabinoid Receptor Agonists; D009281:Naphthalenes; D010919:Placebos; C541946:cannabinoid receptor agonist 13